| Title |
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, January 2017
|
| DOI | 10.1007/s00259-016-3609-9 |
| Pubmed ID | |
| Authors |
Lorenza Scarpa, Sabine Buxbaum, Dorota Kendler, Katharina Fink, Jasmin Bektic, Leonhard Gruber, Clemens Decristoforo, Christian Uprimny, Peter Lukas, Wolfgang Horninger, Irene Virgolini |
| Abstract |
A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Ten consecutive mCRPC patients were selected for (177)Lu-PSMA617 therapy on the basis of PSMA-targeted (68)Ga-PSMA-HBED-CC PET/CT diagnosis showing extensive and progressive tumour load. Following dosimetry along with the first therapy cycle restaging ((68)Ga-PSMA-HBED-CC and (18)F-NaF PET/CT) was performed after 2 and 3 therapy cycles (each 6.1 ± 0.3 GBq, range 5.4-6.5 GBq) given intravenously over 30 minutes, 9 ± 1 weeks apart. PET/CT scans were compared to (177)Lu-PSMA617 24-hour whole-body scans and contrast-enhanced dual-phase CT. Detailed comparison of SUVmax values and absorbed tumour doses was performed. (177)Lu-PSMA617 dosimetry indicated high tumour doses for skeletal (3.4 ± 1.9 Gy/GBq; range 1.1-7.2 Gy/GBq), lymph node (2.6 ± 0.4 Gy/GBq; range 2.3-2.9 Gy/GBq) as well as liver (2.4 ± 0.8 Gy/GBq; range 1.7-3.3 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 18 ± 0.3 GBq. Three patients showed partial remission, three mixed response, one stable and three progressive disease. Decreased (177)Lu-PSMA617 and (68)Ga-PSMA-HBED-CC uptake (mean SUVmax values 20.2 before and 15.0 after 2 cycles and 11.5 after 3 cycles, p < 0.05) was found in 41/54 skeletal lesions, 12/13 lymph node metastases, 3/5 visceral metastases and 4/4 primary PC lesions. Due to substantial individual variance, dosimetry is mandatory for a patient-specific approach following (177)Lu-PSMA617 therapy. Higher activities and/or shorter treatment intervals should be applied in a larger prospective study. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Brazil | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| Unknown | 101 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 17% |
| Student > Master | 11 | 11% |
| Other | 10 | 10% |
| Unspecified | 8 | 8% |
| Student > Ph. D. Student | 7 | 7% |
| Other | 21 | 21% |
| Unknown | 28 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 31% |
| Unspecified | 8 | 8% |
| Physics and Astronomy | 6 | 6% |
| Nursing and Health Professions | 5 | 5% |
| Engineering | 5 | 5% |
| Other | 17 | 17% |
| Unknown | 29 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2021.
All research outputs
#2,716,752
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#215
of 3,083 outputs
Outputs of similar age
#55,623
of 425,996 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#2
of 41 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,996 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.